Theme for this year's virtual event is delivering digital impact at scale.
This year's Indegene Digital Summit takes off as a multi-week, virtual event on September 25, with the next sessions on October 2 and October 16.
Scott Gottlieb, MD, former commissioner of the Food & Drug Administration, will deliver the keynote address. He will be joined by other keynote speakers including Sebastian Guth, PhD (President, Americas Region, Bayer Pharmaceuticals), Daniel Kraft, MD (Chair for Medicine, Singularity University and Founder and Chair, Exponential Medicine), Richard Ashworth, (President, CEO, and Board Member, Tivity Health; Former President, Walgreens), and Aseem Puri, (Chief Marketing Officer, Unilever International). The theme for this year’s summit is Life Sciences’ Digital Leap from x to 10x – delivering digital impact @ scale.
“The current environment has accelerated the need for a digital reset in the life sciences industry, enabling business leaders to scale up a wide range of digital initiatives. The industry now needs to move away from isolated pockets of excellence and experimentation to a steady, integrated state and scale across the organization,” commented Gaurav Kapoor, EVP, Global Product Commercialization and Co-founder, Indegene,
The event will go live with 60+ speakers and 18+ sessions, with 1500+ attendees joining virtually from across the globe. The participants can also experience unique networking opportunities through mobile app, attendee roundtables, and networking lounge.
Click here for a 1-min preview video. To learn more and register for the Summit, click here.
What Every Pharma CEO Should Know About Unlocking the Potential of Scientific Data
December 11th 2024When integrated into pharmaceutical enterprises, scientific data has the potential to drive organizational growth and innovation. Mikael Hagstroem, CEO at leading laboratory informatics provider LabVantage Solutions, discusses how technology partners add significant value to pharmaceutical R&D, in addition to manufacturing quality.
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.